Equimune, mycobacterium cell wall fraction (MCWF) immuno-stimulant, is approved by the APVMA for the treatment of Equine
Respiratory Disease Complex (ERDC) of viral origin. The common causes of ERDC are equine herpesvirus (rhinopneumonitis), influenza
A equine-1 (H7N7) and influenza A equine-2 (H3N8). A serious respiratory infection can ruin years of training invested in the
equine athlete. Studies have shown that a single dose of Equimune administered by IV injection generates a non-specific
amplification of the immune response to antigens. Optimum treatment timing is at the onset of disease during the arly acute period.
Treatment at this time boosts the early immune response, allowing less time for the invading organism to become established and
cause significant cellular damage. The product is safe to use in pregnant mares. Minimize lung damage. Stimulate the healing
process. Rapidly return the equine athlete to normal. For the treatment of equine respiratory disease. APVMA No. 51105 Approved.
Respiratory Disease Complex (ERDC) of viral origin. The common causes of ERDC are equine herpesvirus (rhinopneumonitis), influenza
A equine-1 (H7N7) and influenza A equine-2 (H3N8). A serious respiratory infection can ruin years of training invested in the
equine athlete. Studies have shown that a single dose of Equimune administered by IV injection generates a non-specific
amplification of the immune response to antigens. Optimum treatment timing is at the onset of disease during the arly acute period.
Treatment at this time boosts the early immune response, allowing less time for the invading organism to become established and
cause significant cellular damage. The product is safe to use in pregnant mares. Minimize lung damage. Stimulate the healing
process. Rapidly return the equine athlete to normal. For the treatment of equine respiratory disease. APVMA No. 51105 Approved.